oral pan-coronavirus antiviral, rev. covalent

Ph. III candidate for COVID-19 (300 mg BID)

from SARS-CoV-1 inhibitor (WO2005113580)

Science

Pfizer Worldwide Research

1.  This month’s cover molecule, Pfizer’s PF-07321332 (API of Paxlovid) is an oral, reversible covalent SARS-CoV-2 main protease inhibitor, which has been submitted to the FDA by Pfizer for emergency approval…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks